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Abstract
Background: Dysregulation of microRNA (miRNA) expression in various tissues and body fluids has been demonstrated to
be associated with several diseases, including Type 2 Diabetes mellitus (T2D). Here, we compare miRNA expression profiles
in different tissues (pancreas, liver, adipose and skeletal muscle) as well as in blood samples from T2D rat model and
highlight the potential of circulating miRNAs as biomarkers of T2D. In parallel, we have examined the expression profiles of
miRNAs in blood samples from Impaired Fasting Glucose (IFG) and T2D male patients.
Methodology/Principal Findings: Employing miRNA microarray and stem-loop real-time RT-PCR, we identify four novel
miRNAs, miR-144, miR-146a, miR-150 and miR-182 in addition to four previously reported diabetes-related miRNAs,
miR-192, miR-29a, miR-30d and miR-320a, as potential signature miRNAs that distinguished IFG and T2D. Of these
microRNAs, miR-144 that promotes erythropoiesis has been found to be highly up-regulated. Increased circulating
level of miR-144 has been found to correlate with down-regulation of its predicted target, insulin receptor substrate 1
(IRS1) at both mRNA and protein levels. We could also experimentally demonstrate that IRS1 is indeed the target of
miR-144.
Conclusion: We demonstrate that peripheral blood microRNAs can be developed as unique biomarkers that are reflective
and predictive of metabolic health and disorder. We have also identified signature miRNAs which could possibly explain the
pathogenesis of T2D and the significance of miR-144 in insulin signaling.
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Introduction
The discovery of microRNAs (miRNAs) by Ambros and co-
workers in 1993 has introduced another level of intricacy in the
regulation of the genome [1]. While miRNAs mainly inhibits
translation by binding to the 39 untranslated region (39UTR) of
their target mRNA [2], they are also known to induce gene
activation [3–6]. Since their discovery, miRNAs have become the
focus of intensive research and indentified as key regulators in
governing physiological and pathological processes [7–10]. Besides
their recognized intracellular regulatory function, growing evi-
dence suggests that miRNAs show stable extracellular existence.
These circulating miRNAs are detected in body fluids including
saliva, urine and blood [11,12]. Recently, there have been a
growing number of blood-based miRNA profiling studies which
reported perturbations in the expression of blood miRNAs and
introduced the concept that circulating miRNAs hold much
potential as fingerprints of several diseases [13–18] including Type
2 diabetes (T2D) [19,20]. A recent study by Laterza et al [21]
established the general principle that biomarkers of disease are
secreted into the systemic circulation upon tissue injury. The team
then demonstrated how circulating miRNAs may serve as
potential indicators of what is happening at tissue level. An
independent investigation by Kosaka et al [22] has also reported
how these circulatory miRNAs are released through secretory
machinery and then transferred to the recipients where they can
resume their functions. One possible secretory machinery is the
exosomes, microvesicles that are present in biological fluids such as
urine, saliva and blood [23–26]. Within these exosomes are
cellular gene products including miRNAs, mRNAs, and proteins
that can be transferred to recipient cells to carry out specific
molecular functions [27]. Such interactions allow exosomes
mediate cell-to-cell communication by facilitating the exchange
of molecular components. Based on these reports, we can now
perform blood-based miRNA profiling to search for fingerprints
of diseases. To date, many researchers have proven that a
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identification of biomarkers is extremely valuable and useful in
diseases including diabetes [13–19].
T2D is one of the most prevalent metabolic disorders, and it is
estimated to affect more than 400 million by 2030, of which more
than half will be living in Asia. T2D is postulated to arise from an
interplay of genetic and environmental/epigenetic factors which
leads to a decline in insulin action, followed by a chronic
pancreatic beta-cell dysfunction. When reduction in insulin
function (insulin resistance) occurs, euglycemia is maintained by
increased insulin secretion (hyperinsulinemia). Progressive deteri-
oration in insulin sensitivity and reduction in pancreatic insulin
secretion, create a state of relative insulin deficiency, resulting in
hyperglycemia, presenting as impaired fasting glucose (IFG) at
early stage or T2D at advanced stage [28]. Despite progress made
in the study of mechanisms underlying IFG and T2D [29], the
understanding of these metabolic disorders at molecular level
remains to be elucidated.
Among more than 10000 miRNAs identified in 115 species so
far [Sanger miRNA database release 14.0 http://www.mirbase.
org/], only a handful have been linked to glucose metabolism and
metabolic disorders [30]. Among them, miR-375 that is
abundantly expressed in pancreatic and beta cells, negatively
regulates glucose-stimulated insulin secretion via myotrophin
(Mtpn) inhibition [31,32]. Other miRNAs predicted to target Mtpn
include miR-124a and let-7b [33]. Up-regulation of miR-29a/b
observed in diabetic animal models has also been shown to induce
insulin resistance in cell culture [34]. Altered expression of miR-
192 and miR-377 has also been reported in diabetic kidney
glomeruli and diabetic nephropathy respectively [35,36]. Most
miRNA studies relating to T2D were carried out in either animal
or cell culture models [37–40] and a few in heterogeneous groups
of patients with T2D, who may have had differences in terms of
clinical phenotype and medications used for treatment [19,41,42].
In this report, we compare the miRNA expression in rat model of
T2D with carefully phenotyped newly diagnosed pre-diabetic
(IFG) and overt diabetic (T2D) patients who are not on any
medication. IFG patients are included in the study so as to gain
further understanding in the transition of miRNA expression from
pre-diabetes stage to overt T2D. In addition, using animal models
we have explored the relevance of circulating blood miRNAs to
that of different tissues in T2D pathogenesis. Among the eight
miRNAs identified, miR-144 remained highly up-regulated in
T2D in both cases. In this study, we have also provided evidence
that miR-144 directly inhibits IRS1, a key molecule in insulin
signaling.
Results
Induction of T2D in male Wistar rats
Animals were fed with either normal diet (NFD) or high fat diet
(HFD) for two weeks before a low dose STZ (40 mg/kg) was
administered intra-peritoneally to the HFD group. Combination
of high-fat diet and low dose of STZ injection has been widely
used to induce T2D in rats and proven to effectively induce T2D
whereby the pattern of disease onset and development appears to
be closely analogous to that in the human syndrome [43–45]. This
approach is preferred to administrating single high dose of STZ
which results in Type 1 Diabetes characteristics [46–48]. The
effects of the treatment on body weight, glucose, insulin,
cholesterol and triglycerides concentrations are listed on Table 1.
These results show that the HFD rats weighed approximately 20 g
more than the NFD rats. Although the serum cholesterol level of
the two groups were similar, HFD rats showed significantly higher
serum levels of triglycerides, glucose and insulin. Figure 1 shows
the serum glucose and insulin levels after oral glucose tolerance
test (OGTT). NFD rats showed a peak increase in their serum
glucose concentration at 15 min (,20mmol/L) after glucose
intake but was reduced quickly to normal level within 2 hours
(,12mmol/L). On the contrary, serum glucose concentration of
HFD rats increased rapidly and remained at high level even at
2 hours after glucose intake (,40mmol/L). The insulin response
was almost 3-times higher in the HFD rats as compared with their
NFD controls. Despite the higher insulin concentration, glucose
level was approximately 3-times higher in HFD rats indicating a
state of hyperglycemia and insulin resistance.
miRNA profiling in blood and tissue samples of T2D-
induced rats
To understand the relevance of circulating blood miRNAs
expression to those selected tissues, we performed miRNA
microarray to compare the miRNA expression in blood and four
diabetes-related tissues namely, pancreas, liver, adipose and
skeletal muscles. Only miRNAs that are conserved in humans
have been taken into account. miRNA microarray data was
evaluated after filtering off those miRNAs that showed signal
intensities of 300 and below. Approximately 200 miRNAs were
detected among the five sources of miRNAs. Differential miRNA
Table 1. Effect of STZ administration on HFD rats as compared to NFD healthy controls.
Before Treatment After treatment (2 weeks later)
Control (NFD) HFD/STZ induced T2D Control (NFD) HFD/STZ induced T2D
Weight 204.6764.55 211.6763.78 336.3365.58 359.3368.03 *
Cholesterol (mmol/L) 2.4860.11 2.4760.10 1.9960.14 2.3260.10
Triglycerides (mmol/L) 1.7261.05 2.0660.15 1.2260.18 3.1860.17 *
HDL-C (mmol/L) 0.9460.05 0.8360.06 0.4460.05 0.5560.03
LDL-C (mmol/L) 0.9460.09 0.8660.10 0.8760.16 0.6360.15
Glucose (mmol/L) 8.2760.74 8.9360.26 11.5361.23 30.0863.45 *
Insulin (mU/L) 0.1160.01 0.1060.00 0.1360.00 0.3360.02 *
NFD, normal diet healthy controls; HFD, high fat diet; STZ, streptozotocin; LDL-C, low-density lipoprotein cholesterol; HDL-C; high-density lipoprotein cholesterol. Values
are mean 6 SD with n=6 for each group. Statistically significant differences are tested at p,0.05 significance, denoted by*.
doi:10.1371/journal.pone.0022839.t001
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model (HFD group) compared to that of control (NFD group) are
presented in a hierarchical clustering plot (heatmap) generated
using the TIGR multiple experimental viewer software (Fig. 2A,
Table S1, GEO Accession No. GSE26167; SuperSeries
GSE26168). Figure 2A shows that blood miRNAs are clustered
closely to that of the insulin-targeted tissues, first being the skeletal
muscles followed by adipose and then liver. Pancreas which
secretes insulin, has more miRNAs being up-regulated and was
clustered away on the left of the heatmap. To focus on the more
important miRNAs, we have selected those miRNAs that showed
significant changes as compared to control (p,0.05). The number
of miRNAs that showed significant changes in any of the five
sources is displayed in a Venn diagram (Fig. 2B). On average, each
source has approximately 130 miRNAs that showed significant
changes in HFD compared to NFD. Among these, 84 miRNAs are
detected in all five sources. The heatmap clustered blood miRNAs
in the centre of the peripheral tissues and the Venn diagram
showed that most miRNAs detected in the peripheral tissues were
similarly detected in the blood. Moreover, a recent blood-based
miRNA profiling study led by Heneghan et al [13] compared the
different circulating medium (serum, plasma, or whole blood) to
find out which best represented miRNA levels. The team reported
that higher yields of miRNAs were obtained from whole blood,
compared with either serum or plasma and that there was no
significant difference between the mean white cell, hemoglobin or
hematocrit levels among the samples used (controls versus cases).
This finding further strengthened the notion that the whole blood
is the preferred source for studying circulating miRNAs. From the
pool of miRNAs that showed significant changes, we focused our
investigation on those that showed at least 61.5 fold change
(Table S2). We identified miR-146a, miR-182 and miR-30d to be
among the highly down-regulated miRNAs across all five sources.
miR-146a expression was the lowest in the adipose (24.6260.036)
while miR-30d which was postulated to participate in insulin
gene transcription [49], showed the lowest expression in pan-
creas (22.8160.004). miR-182 was also down-regulated in
all five tissues with the lowest expression observed in skeletal
muscle (24.2360.548). In all five sources, miR-144, miR-150,
miR-192, miR-29a and miR-320a were found to be highly up-
regulated. Association of miR-192 [35], miR-29a [34] and miR-
320 [50,51] in T2D has been reported in previous studies and our
study also shows similar results. miR-144 showed the highest up-
regulation among other miRNAs in three tissues namely pancreas
(7.9460.171), adipose (4.3460.178) and liver (4.2660.174).
Similarly, up-regulation of miR-150 was observed to be highest
in the adipose (3.2160.197) followed by liver (2.0760.388). Using
these results, we then extended our study to the peripheral blood
samples of individual with IFG or T2D.
Characteristics of IFG and T2D male patients
Based on the miRNA profiles from animal tissues of T2D
model, we observed that expression of circulating blood
miRNAs is generally reflective of that in pancreas and insulin-
target tissues. IFG patients were included in the study to gain
further understanding in the transition of miRNA expression
from pre-diabetes stage to T2D. A total 50 males were selected
from 158 individuals recruited for health screening. The
selected individuals had a mean age of 40.569.1 years, fasting
glucose 5.161.3 mmol/L, SBP 129.0615.1 mmHg and DBP
82.269.6 mmHg. From these, a group of twenty-one age-
matched individuals were selected as the first batch (Batch A)
and categorized into Control, CTL (n=7), Impaired Fasting
Glucose, IFG (n=6) and Type 2 Diabetes, T2D (n=8) for the
study. Their BMI was #27 [52]. Table 2 describes the
demography of these individuals. After investigating the
distinctive miRNA expression profiles from this first batch of
IFG and T2D individuals, a second batch of individuals
(Table 2- Batch B) with CTL (n=8), IFG (n=8) and T2D
(n=13) was selected to validate the expression of the potential
signature miRNAs in the two metabolic conditions.
miRNA profiles of T2D rat model and T2D patients
Figure 3A displays the hierarchical clustering of the miRNA
profiles in T2D rat model and pooled T2D patients. We have
shown previously that the rat blood miRNA profile (Fig. 2A) is
Figure 1. Oral glucose tolerance test (OGTT). Serum glucose and insulin concentrations of both NFD and HFD groups upon OGTT. Data
presented as mean 6 SEM with n=6 for each group. Statistically significant differences are tested at p,0.05 significance. *p,0.05, **p,0.01,
***p,0.001.
doi:10.1371/journal.pone.0022839.g001
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F i g u r e3 A ,i ti sa p p a r e n tt h a tt h eb l o o dm i R N Ap r o f i l e so f
the pooled T2D patients and the T2D rat model are clustered
i no n eb r a n c h ,w i t ht h er a tp a n c r e a sm i R N Ap r o f i l e
segregating independent to the others. The PCA plot of the
miRNA profiles of these six groups also shows their relation-
ships to each other (Fig. 3B).
miRNA profiling in patients (Batch A)
Next, we evaluated the total blood miRNA profile of both IFG
and T2D patients to observe how the miRNA expression change
as the disease develops. About 200 miRNAs with background
subtracted mean signal intensities .300 were detected in each
group. The expression patterns of blood miRNAs in IFG and T2D
compared to that of CTL are presented in a hierarchical clustering
Figure 2. Clustering of miRNA profiles of blood and tissues of HFD rats. A. Hierarchical clustering plot (heatmap) of miRNA
distribution in blood and tissues of HFD rats (compared to controls). Only miRNAs conserved in humans with background subtracted mean
signal intensities above 300 are included. Expression of blood miRNAs are clustered in the centre closely to the peripheral tissues. Data are expressed
as fold change of HFD versus NFD control. Green: down-regulation; Red: up-regulation; Grey: not detected. B. Venn diagram showing the
number of miRNAs with significant changes detected in blood and the different tissues (Diabetic vs controls). 84 miRNAs have been
detected in all five sources.
doi:10.1371/journal.pone.0022839.g002
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viewer software (Fig. 4A). This indicated a closer relationship in
miRNA expression among patients within the same group (i.e.
IFG patients were clustered on one branch and T2D patients on
the other). PCA (Fig. 4B) also showed a distinctive distribution of
individuals with IFG and T2D. Compared to that of CTL,
approximately 50 miRNAs were up-regulated while about 70
miRNAs were down-regulated in the IFG group (Fig. 4A, Table
S3). The T2D group showed approximately 70 miRNAs to be up-
regulated and about 100 miRNAs to be down-regulated (Fig 4A,
Table S3, GEO Accession No. GSE21321; SuperSeries
GSE26168).
As the two groups showed differential miRNA profiles, we next
explored for significant miRNA changes within each group. This
was achieved with the next level of filtering in which we discarded
miRNA changes that were not significant (p.0.05) and not
replicated in at least 50% of the subjects in any of the two
categories (IFG or T2D as compared to CTL). Approximately 120
miRNAs passed through this second stage of filtering (Table S4).
Pearson Correlation scatter plots on these miRNAs indicated a
weak correlation between IFG and CTL subjects with R value of
0.78 (Table S5A) and a much more weaker correlation (R=0.68)
between T2D and CTL (Table S5B). We compared the
expressions of these miRNAs between IFG and T2D group
(Table S4) and identified miRNAs that could distinguish the two
metabolic conditions. The eight miRNAs (miR-144, miR-146a,
miR-150, mR-182, miR-192, miR-29a, miR-30d and miR-320)
which were previously identified in the rat study showed similar
expression in the patients’ blood miRNAs. These eight miRNAs
were then selected for further investigation.
miRNA stem-loop real-time RT-PCR and mRNA targets
The eight miRNAs identified could potentially form a signature
to distinguish IFG and T2D (Fig. 5A). We validated these
microarray data using stem-loop real-time RT-PCR and we
observed that the results were consistent with our microarray data
(Fig. 5B). miR-144 and miR-192 were among the highly up-
regulated miRNAs in T2D. In contrast, miR-192 expression
remained close to basal level in the IFG group while miR-144
showed a significant up-regulation against healthy controls but at a
lower fold change compared to that in T2D (IFG: 1.38560.14;
T2D: 3.07060.13). miR-29a and miR-320 that have been
previously found to show altered expression in diabetic models
[34,49,50], also showed a significant up-regulation in the T2D
samples in our study. miR-150, miR-182 and miR-30d showed
contrasting expressions in IFG and T2D while miR-146a was
down-regulated in both cases.
To gain further insight on how these eight miRNAs participate in
T2D development, we used the available databases to search for
their potential mRNA targets that are related to glucose
homeostasis. miR-30d expression has been strongly associated to
insulin gene transcription [49], while miR-320 was reported to
affect the AKT signaling pathway [50]. In this study, we tested this
hypothesis by comparing miR-30d and miR-320a expression with
respect to insulin (INS) and AKT mRNA levels respectively. We next
queried how the other miRNA alterations relate to mRNA
expression. We searched the five best target prediction databases
namely RegRNA [http://regrna.mbc.nctu.edu.tw/], MirBase
[http://microrna.sanger.ac.uk/cgi-bin/targets/v5/search.pl], Tar-
getScan [http://www.targetscan.org/], Mirgen [http://www.
diana.pcbi.upenn.edu/cgi-bin/miRGen/v3/Targets.cgi] and mi-
croRNA.org [http://www.microrna.org/microrna/getGeneForm.
do] to look for genes that play key roles in the insulin pathway as
potential targets of the dysregulated miRNAs. Here, we considered
six insulin signaling related mRNAs that encode insulin receptor
(INSR), glucose transporter 4 (GLUT4), insulin receptor substrate 1
(IRS1), Cas-Br-M murine ecotropic retroviral transforming se-
quence homolog (CBL), forkhead box O1 (FOXO1) and protein-
tyrosine phosphatase nonreceptor-type 1 (PTPN1) as potential
targets for the selected miRNAs (when detected in at least three of
the five databases).
To verify the relationship between miRNAs and their potential
mRNA targets, we also carried out mRNA microarray on the
peripheral blood of IFG and T2D individuals (Table S6 shows
expression of genes of interest; GEO Accession No. GSE21321).
PCA was then plotted based on the mRNA profiles to study the
distribution of the participants (Table S7). We observed that
microRNA profiling gives a more accurate prediction of the
participants’ metabolic status rather than mRNA profiling. With
particular focus on the genes identified above, we compared their
mRNA expressions with the corresponding predicted miRNA
modulators (Table S8). Quantitative real-time PCR was used to
validate the mRNA microarray results for these mRNAs. The
eight mRNAs have been found to be differentially expressed in
Table 2. Clinical characteristics of study participants.
CTL IFG T2D
Batch A (n=7) B (n=8) A (n=6) B (n=8) A (n=8) B (n=13)
Age (years) 46.367.5 43.365.7 49.067.6 48.0610.4 46.763.4 41.0612.1
BMI 22.462.3 24.463.1 24.162.7 30.063.9 24.561.1 28.064.9
Fasting glucose #6.0mmol/L 4.760.7
* 4.760.5
* 6.460.1
* 6.460.1
* 8.861.9
* 10.664.3
*
TC #5.0 mmol/L 4.660.6 4.560.8 4.760.4 5.260.8 4.860.2 5.861.1
LDL #3.4mmol/L 2.960.4 2.660.5 2.960.7 3.360.8 3.060.3 3.460.8
SBP #140 mmHg 121.3611.9 117.767.1 125.8615.1 125.0610.5 125611.2 129618.6
DBP #90 mmHg 75.369.2 71.367.8 80.4610.0 82.069.6 79.766.4 78.0610.6
All participants in batch A were normotensive with desirable cholesterol levels and BMI #27. Participants in batch B showed minor differences in values for total
cholesterol and BMI.
Normal values for each measurement are indicated in italics. CTL, healthy controls with fasting glucose ,6.1 mmol/l; IFG, impaired fasting glucose with fasting glucose
above 6.0mmol/l but less than 7.0 mmol/l; T2D, type 2 diabetes with fasting glucose greater or equal to 7.0mmol/l; TC, total cholesterol; LDL-C, low-density lipoprotein
cholesterol; HDL-C; high-density lipoprotein cholesterol; SBP, systolic blood pressure; DBP, diastolic blood pressure. Values are mean 6 SD. Statistically significant
differences are tested at p,0.05 significance, denoted by*.
doi:10.1371/journal.pone.0022839.t002
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expression patterns of their respective potential miRNA regulators.
Most of them showed contrasting results between IFG and T2D,
with the exception of insulin receptor substrate 1 (IRS1). Besides
miR-192 [35] and miR-29a [34] which have previously been
shown to be implicated in diabetes, we have also observed an
approximately linear relationship between miR-144 expression
and increasing glycaemic status (from IFG to T2D).
Validation of miRNA and mRNA expression with another
batch of patients (Batch B)
To verify the potential signature miRNAs in IFG and T2D, we
validated the expression of the selected miRNAs and mRNAs in
another batch of individuals who were not on medication during
the time of recruitment and were newly diagnosed with either IFG
or T2D (Table 2, Batch B). Differential miRNA and mRNA
expression were observed in the two cases as quantified by stem-
loop real-time RT-PCR and real-time PCR (Table S9). The
heatmap showed inverse relationship between miRNAs (Fig. 6A)
and their potential mRNA targets (Fig. 6B) which was consistent
with the observation from the previous batch (Batch A).
miRNA and mRNA targets in the blood, tissues and
exosomes of rat model
Since different tissues may have different abundance levels of
the miRNAs of interest, we investigated how each organ
contributes to the circulating miRNA pool we observed in the
blood. To assess this, we employed stem-loop real-time RT-PCR
Figure 3. Clustering of miRNA profiles of HFD rats and pooled T2D patients. A. Hierarchical clustering plot (heatmap) of miRNA
distribution in HFD rats and pooled blood from T2D patients. Blood samples from HFD rats and pooled T2D patients are clustered closely to
one another. Data are expressed as fold change of HFD versus NFD control. Green: down-regulation; Red: up-regulation; Grey: not detected. B.
Principal component analysis (PCA) showed similar clustering as heatmap.
doi:10.1371/journal.pone.0022839.g003
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(pancreas, liver, skeletal muscle and adipose), blood and also
exosomes from control rats (Table S10). In general, miRNAs are
found in greater abundance in the blood as compared to that in
exosomes. This could be due to the fact that the blood contains
other sources of miRNAs such as leukocytes which could
contribute to the miRNA pool. miR-29a, miR-30d, miR-150
and miR-320 are all highly expressed in adipose, skeletal muscle
and liver tissues with lower abundance in pancreas. miR-144,
miR-146, miR-182 and miR-192 showed a lower expression
Figure 4. Clustering of miRNA profiles of IFG and T2D patients (Batch A). A. Hierarchical clustering plot (heatmap) of miRNA
distribution in IFG and T2D patients. Only miRNAs with background subtracted mean signal intensities above 300 are included. Data are
expressed as fold change of case versus healthy control. Green: down-regulation; Red: up-regulation; Grey: not detected. B. Principal component
analysis (PCA) plot showed a distinguished distribution of IFG and T2D patients based on miRNA expression. Batch A patients consists
of six IFG patients (labeled as 1 IFG to 6 IFG) and eight T2D patients (labeled as 1 T2D to 8 T2D). CTL, healthy controls; IFG, impaired fasting glucose;
T2D, type 2 diabetes.
doi:10.1371/journal.pone.0022839.g004
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as well as in the pancreas. A more uniform expression level of
miRNAs is observed in the insulin-target tissues in contrast to
pancreas, the insulin-secreting organ.
We have also quantitated the mRNA abundance levels in all
tissues along with blood and exosomes (Table S10). We also
measured both INS1 and INS2 mRNA levels since rats carry
these two insulin genes. Interestingly, the expression levels of
nine mRNAs (A K T 2 ,C B L ,F O X O 1 ,G L U T 4 ,I N S 1 ,I N S 2 ,I N S R ,
IRS1 and PTPN1) was found to be highest in skeletal muscle and
liver, followed by pancreas and lowest in the adipose tissue.
Subsequently, when the tissues from diabetic rats were
subjected to quantitative stem-loop PCR, we observed a
significantly dysregulated pattern of expression for the eight
miRNAs under investigation (Fig. 7A). miR-29a, miR-144,
miR-150, miR-192 and miR-320 showed an up-regulation from
that of control samples whereas miR-30d, miR-146a and miR-
182 showed down-regulation. As expected, the expression of
respective target mRNAs exhibited an inverse expression
pattern (Fig.7B)
Expression of potential ‘signature miRNAs’ in islets
subjected to high glucose treatment
In addition to animal and human studies, we also performed
primary cell culture studies using islets isolated from the pancreas
of normal rats. These islets were then subjected to two different
glucose concentrations; 5 mM (basal glucose) and 25 mM (high
glucose). Total RNA extracted from these two treatment groups
were then used to quantitate the eight miRNAs under study along
with their predicted mRNA targets (Fig. 8, Table S11). In contrast
to our previous observations, miR-30d was found to be highly up-
regulated (2.96960.18) which corresponded to increased expres-
sion of INS1 and INS2, 7.75760.19 and 5.50060.21 respectively
in response to high glucose condition. This difference could be due
to the early onset of insulin deficiency in T2D in which b-cell
dysfunction has not fully occurred like in the case of our animal
model where low dose of STZ could initiate b-cell destruction as
observed in overt T2D. Correspondingly, in the high glucose
media, expression of miR-144 was found to be highest
(3.60560.21) accompanied by a down-regulation of IRS1
(23.25760.29), followed by miR-150 (2.90460.19) and miR-
Figure 5. Identification of ‘signature miRNAs’ expressed in IFG and T2D (Batch A). A. Heatmap of the potential ‘signature miRNAs’
expressed in IFG and T2D. B. Quantitative stem-loop RT-PCR of eight selected miRNAs in IFG (checkered bars) and T2D (black bars)
against CTL (white bars) and C. Real-time PCR of respective predicted mRNA targets in IFG (checkered bars) and T2D (black bars)
against CTL (white bars). Data presented as mean 6 SEM of both individual and pooled samples of each category. Fold change below one are
expressed as negative values. Validation is done in triplicates. Statistically significant differences are tested at p,0.05 significance. *p,0.05, **p,0.01,
***p,0.001. Batch A patients consists of six IFG patients (labeled as 1 IFG to 6 IFG) and eight T2D patients (labeled as 1 T2D to 8 T2D). CTL, healthy
controls; IFG, impaired fasting glucose; T2D, type 2 diabetes. Green: down-regulation; Red: up-regulation; Grey: not detected. Predictions: miR-144/
IRS1; miR-146a/PTPN1; miR-150/GLUT4 and CBL; miR-182/FOXO1; miR-192/INSR; miR-30d/INS; miR-29a and miR-320/AKT2.
doi:10.1371/journal.pone.0022839.g005
Figure 6. Comparison of miRNA expressions with its corresponding predicted mRNA targets (Batch B). A. A heatmap of quantitative
stem-loop RT-PCR of eight selected miRNAs and B. A heatmap of real-time PCR of respective predicted mRNA targets. Validation has
been done in another independent batch (Batch B) of participants in triplicates. Statistically significant differences are tested at p,0.05 significance.
Batch B patients consists of eight IFG patients (labeled as 7 IFG to 14 IFG) and thirteen T2D patients (labeled as 9 T2D to 21 T2D).CTL, healthy controls;
IFG, impaired fasting glucose; T2D, type 2 diabetes. Green: down-regulation; Red: up-regulation; Grey: not detected. Predictions: miR-144/IRS1; miR-
146a/PTPN1; miR-150/GLUT4 and CBL; miR-182/FOXO1; miR-192/INSR; miR-30d/INS; miR-29a and miR-320/AKT2.
doi:10.1371/journal.pone.0022839.g006
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A. A heatmap of quantitative stem-loop RT-PCR and real-time PCR of selected miRNAs and mRNAs respectively. Samples are obtained
from a combination of low dose STZ and high-fat diet induced T2D rat model. B. A heatmap of quantitative stem-loop RT-PCR and real-time
PCR of selected miRNAs and mRNAs respectively. Samples are obtained from high-fat diet induced T2D rat model. Validation has been done in
triplicates. Statistically significant differences are tested at p,0.05 significance. Green: down-regulation; Red: up-regulation; Grey: not detected.
Predictions: miR-144/IRS1; miR-146a/PTPN1; miR-150/GLUT4 and CBL; miR-182/FOXO1; miR-192/INSR; miR-30d/INS; miR-29a and miR-320/AKT2.
doi:10.1371/journal.pone.0022839.g007
Figure 8. A. Quantitative stem-loop RT-PCR of selected miRNAs in islets with basal glucose concentration of 5 mM (white bars) and
high glucose concentration of 25 mM (black bars) and B. Real-time PCR of respective predicted mRNA targets in with basal glucose
concentration of 5 mM (white bars) and high glucose concentration of 25 mM (black bars). Data presented as mean 6 SEM with n=3 for
each group. Statistically significant differences are tested at p,0.05 significance. *p,0.05, **p,0.01, ***p,0.001. Predictions: miR-144/IRS1; miR-
146a/PTPN1; miR-150/GLUT4 and CBL; miR-182/FOXO1; miR-192/INSR; miR-30d/INS; miR-29a and miR-320/AKT2.
doi:10.1371/journal.pone.0022839.g008
MicroRNAs and Type 2 Diabetes
PLoS ONE | www.plosone.org 10 August 2011 | Volume 6 | Issue 8 | e22839192 (1.98960.20) which are predicted to target GLUT4
(22.60460.25) and CBL (24.67260.31) and INSR (1.1506
0.28) respectively. Likewise, down-regulation of miR-146a
(1.90560.26) was followed by an increased expression of its target
mRNA, PTPN1 (5.17560.28). Marginal expression levels were
observed for miR-182 (21.26760.26) and miR-29a (1.35160.23)
which inversely correlated to their respective predicted mRNA
targets FOXO1 and AKT2 respectively.
Differential expression of IRS-1 and phosphorylated IRS-1
in IFG and T2D
Since insulin-dependent glucose uptake could be compromised
by the over expression of miR-144, we further investigated miR-
144 and its predicted target, IRS1. We compared the IRS1 protein
expression in the two case groups against normal control. As
phosphorylation leads to IRS1 activation, we examined the
protein content for Tyr
612-phospho-IRS1 and Ser
636+639-phos-
pho-IRS1. These two sites of phosphorylation are selected
considering their opposing effects on IRS1 activation. While the
phosphorylation of IRS1 on tyrosine residues is needed to mediate
insulin signaling, phosphorylation of IRS1 on certain serine
residues (Ser-636 and Ser-639) have been shown to terminate
insulin effects [53,54]. As shown in Fig. 9, IRS1 protein content
displayed a decreasing expression from healthy control to disease
groups with T2D. This can imply that IRS1 is highly down-
regulated in T2D in conjunction with its predicted negative
modulator, miR-144 which was up-regulated in T2D. Western
blot of serum samples showed a decreased expression of Tyr
612-P-
IRS1 protein in T2D as compared to that of CTL and IFG, while
the expression of Ser
636+639-P-IRS1 in T2D was highest among
the three groups (Fig. 9).
IRS1 is a direct target of miR-144
There are two different binding sites of miR-144 at the 39 UTR
of IRS1. Table S12 shows the bindings sites of miR-144 at the
39UTR of IRS1 and the different constructs designed to show that
miR-144 directly targets IRS1. To demonstrate that IRS1 is a
direct target of miR-144, we constructed independent reporter
vectors that contained the different combinations of binding sites
of miR-144 at the 39UTR of IRS1 (Table S12) downstream of a
firefly luciferase reporter gene. These constructs were then co-
transfected with anti- or pre-miR-144 into HeLa cells. Cells
transfected with pre-miR-144 exhibited a significant reduction in
the luciferase activity which was reduced further when both miR-
144 binding sites are present (Fig. 10). Likewise, transfection with
anti miR-144 showed an increasing pattern of luciferase activity
from constructs where only one binding site is present to that
where both binding sites are included (Fig. 10). Site-directed
mutagenesis of the miR-144 binding sites abolished interactions
between miR-144 and IRS1 accordingly. These findings indicate
IRS1 forms a direct target of miR-144.
miR-144 regulates IRS1 mRNA expression
Previous reports [55–57] have confirmed that HeLa cells express
miR-144 and IRS1. HeLa cells were then used to assess the
regulatory function of miR-144 on IRS1 and in addition to that, we
also performed the same experiment in an insulin-responsive cell
line, 3T3L1 adipocytes. Basal levels of miR-144 and IRS1 were
measured in both cell lines (Fig. 11A) prior to our subsequent assays.
Based on the prediction that miR-144 binds to the 39UTR of IRS1,
changes in miR-144 expression should be reflected in IRS1 mRNA
levels accordingly. In order to alter miR-144 expression, HeLa and
3T3L1 cells were transfected with pre-miR-144 and anti-miR-144
independently, followed by quantification of the changes in miRNA
and mRNA levels (Fig. 11B, 11C). Introduction of pre-miR-144
increased the miR-144 levels by 43 fold and simultaneous reduction
in the IRS1 mRNA expression (21.62860.18) in HeLa. In 3T3L1
adipocytes treated with pre-miR-144, miR-144 levels increased by
approximately 80 fold which corresponded to decreased IRS1
mRNA level (21.73760.18). Likewise, in anti-miR-144 transfected
HeLa and 3T3L1 cells, the relative expression of miR-144 was
reduced to 0.01960.09 and 0.03360.11 respectively while a
significant increase in IRS1 mRNA level was observed (HeLa:
5.60760.217; 3T3L1: 4.23260.22). Regulation of IRS1 by miR-
144 was further verified by immunocytochemistry and comple-
mentarily, the IRS1 protein expression correlated to that of the gene
Figure 9. Western Blot analysis of IRS1, Tyr
612-phospho-IRS1 and Ser
636+639-phospho-IRS1 in CTL (white bars), IFG (checkered bars)
and T2D (black bars) individuals. The data presented here is a representative of three independent experiments (both individual and pooled
serum samples showed similar profiles) and as mean 6 SEM. Fold change below one are expressed as negative values. Statistically significant
differences are tested at p,0.05 significance.
*p,0.05, **p,0.01, ***p,0.001. CTL, healthy controls; IFG, impaired fasting glucose; T2D, type 2
diabetes.
doi:10.1371/journal.pone.0022839.g009
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reduced fluorescence intensity for IRS1 (Fig. 11D, middle panel)
while the opposite was observed in anti-miR-144 transfected cells
(Fig. 11D, right panel). Altogether, these results suggest that miR-
144 is a modulator of IRS1.
Discussion
Circulating blood miRNAs are reflective of those in
tissues
It has been reported that miRNAs circulating in the blood can
potentially serve as novel noninvasive biomarkers of diseases
including diabetes [13–16,19]. This hypothesis is supported by a
recent study by Kosaka et al [22] which generated the concept of
miRNAs-mediated intercellular communication. He reported that
circulatory miRNAs are released through a secretory mechanism
and conveyed to recipient cells to exert their function. Further-
more, Laterza et al [21] have demonstrated that aberrant
expression of circulating miRNAs corresponds to (origin) tissue
injury. In our T2D animal model, we profiled miRNA expression
in pancreas, three insulin-targeted tissues (adipose, skeletal muscle
and liver) as well as blood to observe the relevance of blood
miRNAs to those in tissues. A similar study has also been carried
out Zhao et al [38], in which the group performed miRNA
profiling in the islets, liver and adipose of diabetes-resistant (B6)
and diabetes-susceptible (BTBR) mice. Zhao et al identified
different groups of miRNAs in different organs which could
potentially participate in the pathogenesis of T2D. Some of the
miRNAs identified by them showed similar expression pattern in
our study as well. miRNAs such as miR-133a, miR-185, miR-152,
miR-34a and miR-342 which were reported to show increased
expression were also up-regulated in our rat model. While miR-
184 and miR-204 which were down-regulated in at least one
mouse strain in their study, also showed down-regulation in our
model. However, there were striking differences in the expression
of miRNAs such as miR-135a, miR-429, miR-200a/b and miR-
215 which were not detected in our samples but were reported to
be significantly decreased by Zhao et al [38]. A possible reason for
these differences could be that these miRNAs were reduced to a
level that is beyond detection. Alternatively, the different species
and methodology being used to induce T2D could also explain the
differences. Zhao et al used the genetic modification approach
while we stimulated T2D by using a combination of high-fat diet
and low dose STZ (40 mg/kg). As indicated in the heatmap
(Fig. 2A), the rat blood miRNA profile was clustered closely to
those from the insulin-targeted tissues. Furthermore the Venn
diagram (Fig. 2B) showed that most of the miRNA changes
detected in the tissues involved in the insulin signaling pathway
can also be detected in the blood miRNA profile. These findings
strengthened the observations made by Kosaka [22] and Laterza
[21] that miRNAs can interact intercellularly and that tissue injury
may result in the secretion of miRNAs. These miRNAs that are
packaged in exosomes are known to be nuclease resistant and
stable in peripheral blood [27]. Based on these reports, we
extended our investigation to profile the miRNAs in human blood
samples.
miRNAs involved in the insulin signaling pathway
The first part of our investigation in T2D animal model study
revealed eight miRNAs that were highly dysregulated in T2D.
These eight miRNAs showed similar expression across all five
sources (pancreas, liver, skeletal muscle, adipose and blood) that
were profiled. Among these eight miRNAs, four of them namely
miR-192 [35], miR-29a [34], miR-30d [49] and miR-320a
[50,51] had previously been reported in earlier studies and our
results were consistent with them. Among the novel miRNAs
(miR-144, miR-146a, miR-150 and miR-182) identified, miR-144
had the highest up-regulation upon T2D in most tissues. However
during the course of our study, involvement of miR-146a in
diabetes was reported by another group of researchers along with
other diabetes-related miRNAs [58,59]. Following that, we carried
out a cross-sectional study involving Asian males and found these
shortlisted eight miRNAs showing differential expression patterns
in the blood samples of IFG and T2D patients. Hence these
Figure 10. Direct inhibitory effect of miR-144 on IRS1. Dual luciferase assay. Quantitation of the effects of pre- or anti- miR-144 interaction with
the 39 UTR of IRS1. Binding sites of miR-144 at 39UTR of IRS1 and mutated constructs of the binding sites are listed in Table S12. The plasmid
constructs together with pre- or anti- miR-144 were co-transfected into HeLa cells. Luminescence for luciferase gene activity in treated samples (pre
or anti miR-144) were obtained 48 hours post-transfection. Relative luminescence was obtained by normalizing the values against control plasmids,
pMIR-REPORT
TM without any 39UTR insert. Data presented as mean 6 SEM with n=3. Fold change below one are expressed as the negative values.
Statistically significant differences are tested at p,0.05 significance.
*p,0.05, **p,0.01, ***p,0.001.
doi:10.1371/journal.pone.0022839.g010
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individuals. Similar to the animal data, miR-144 was again among
the highly up-regulated miRNA that showed a linear increase in
expression with increasing glycaemic status. With the help of
published reports and bioinformatics-based databases, we identi-
fied the potential insulin signaling-related mRNA targets for these
miRNAs (Fig. 5B, 5C). Based on these findings we have proposed
a mechanism on how circulating miRNAs may potentially control
the expression corresponding targets and how their regulatory
networks may govern different stages of the insulin pathway in the
pathogenesis of T2D (Fig. 12) [31,34,46,50,67–69]. miRNAs such
as miR-144, miR-29a and miR-192 that were up-regulated in both
IFG and T2D patients (Table S8) are predicted to target IRS1,
AKT2 and INSR respectively. These genes are involved in the
insulin signaling pathway. Of the above three, only the expression
pattern for miR-144 and its predicted mRNA target, IRS1, are
concordant for both IFG and T2D (Fig. 5B, 5C). miR-144 also
exhibited an approximately linear relationship with increasing
glycaemic status as observed in IFG and T2D patients (Fig. 5B).
We hypothesize that this may represent the primary abnormality
in the pathogenesis of development of abnormal glucose tolerance.
The changes in expression patterns observed in the other mRNA
targets we identified (comparing IFG and T2D with healthy
controls) are either inconsistent or only significantly different in
T2D but not IFG (Fig. 5B, 5C). This may be due to a secondary
effect that could have resulted from the primary abnormality of
down-regulation of IRS1. The differences in expression patterns in
IFG and T2D may represent the loss or impaired adaptive
changes to increased blood glucose in T2D, ultimately resulting in
hyperglycemia. miR-30d and miR-320 which have been shown to
regulate INS and PIK3/Akt signaling [50] exhibited opposite
expression in the two disease groups (Table S8). Insulin production
mainly involves insulin gene transcription which is indicated by the
insulin mRNA levels. The quantitative real-time PCR results
showed that INS mRNA increased in IFG but was negatively
regulated in T2D (Fig. 5C, 6B). This supports the transition of
Figure 11. Expression of IRS1 in HeLa/3T3L1 cells transfected with pre- or anti- miR-144. A. Endogenous levels of miR-144 and IRS1
in HeLa/3T3L1 cells as delta threshold cycle (DCt) value with respect to 18S rRNA. Previous reports [42–44] have also confirmed that miR-
144 and IRS1 are expressed in HeLa cells. B. Relative miR-144 expression in HeLa/3T3L1 cells transfected with either pre- or anti- miR-144
at a concentration of 30 nM. C. Relative IRS1 mRNA expression in HeLa/3T3L1 cells transfected with either pre- or anti- miR-144at a
concentration of 30 nM. Data presented as mean 6 SEM (n=3). Fold change below one are expressed as the negative values. Statistically
significant differences are tested at p,0.05 significance. *p,0.05, **p,0.01, ***p,0.001. D. IRS1 immunoreactives in HeLa cells transfected
with either pre- or anti- miR-144. The cells were fixed and immunolabeled with IRS1 antibody (green) and nuclear stain DAPI (blue). Left panel:
Non-transfected cells; Middle panel: Pre miR-144 transfected cells showed reduced fluorescence intensity; Right panel: Anti miR-144 transfected cells
showed increased fluorescence intensity. The data presented here is a representative of three independent experiments.
doi:10.1371/journal.pone.0022839.g011
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with IFG and T2D respectively. Inhibition of miR-30d has been
found to abolish glucose stimulated insulin gene transcription in
cell culture studies [49]. Our data is in support of this theory in
which reduced expression of miR-30d correlates with down-
regulation of insulin gene in the T2D samples, while, up-
regulation of miR-30d in the IFG group is accompanied with
increased levels of insulin mRNA (Fig. 5B, 6A). Our data suggests
unlike most other miRNAs which are inhibitory, miR-30d may
be functioning as an RNA activator to insulin gene expression.
The final stage of insulin signaling is the translocation of glucose
transporter-4 (GLUT4) from the intracellular storage to the
plasma membrane of the insulin responsive cells to allow uptake
of glucose [60]. V-akt murine thymoma viral oncogene homolog
2( AKT2) and Cas-Br-M (murine) ecotropic retroviral transform-
ing sequence (CBL) are two molecules responsible for this event.
We found mRNA for AKT2 to be maintained at basal level in
IFG but greatly reduced in T2D (Fig. 5C, 6B). This differential
expression suggests a mechanism in which, insulin signaling is
impaired in T2D. On the other hand, CBL (a second cue for
GLUT4 translocation) was up-regulated in IFG but reduced in
T2D (Fig. 5C, 6B). This could imply a compensatory mechanism
to maintain effective GLUT4 translocation in IFG, lost in T2D.
These are associated with the down-regulation of GLUT4, a key
effector of insulin action, in T2D. CBL and GLUT4 are potential
targets of miR-150, while miR-320 inhibits PI3-K/Akt signaling
[50]. Once again, the inverse pattern between miRNA and their
mRNA target expression is demonstrated by both miR-150 and
miR-320a up-regulation in T2D subjects (Fig. 5B, 6A).
Binding of insulin to insulin receptor may be suppressed by
several inhibitors such as PTPN1, a potential mRNA target of
miR-146a. When expressed at normal levels, this miRNA may act
as a suppressor of PTPN1 to allow insulin signaling. However,
reduced expression of miR-146a may lift the suppression of
PTPN1 gene, allowing the latter to impair insulin signaling. We
have found that down-regulation of miR-146a to be greater in
T2D than IFG (Fig. 5B, 6A). This observation correlates with the
expression of PTPN1 which remained at basal level in IFG but
increased in T2D (Fig. 5C, 6B). Increased levels of PTPN1 will
inhibit insulin signaling by removing phosphate groups of the
effector molecules thus aborting the downstream events. Hence
these observations further suggest that insulin signaling is inhibited
to a greater degree in T2D, even in newly diagnosed stage, as in
our study.
In addition to promoting glucose uptake, insulin inhibits pro-
duction and release of glucose by blocking hepatic gluconeogenesis.
Figure 12. Possible mode of mechanism on miRNA-regulatory networks. Possible ways in which miRNA govern different stages of the
insulin pathway in the pathogenesis of Type 2 Diabetes. miRNAs that have been reported in previous studies are indicated in brackets while those
underlined are predicted by the five best target prediction databases namely RegRNA, MirBase, TargetScan, Mirgen and microRNA.org.
doi:10.1371/journal.pone.0022839.g012
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transcription factors, plays a role in hepatic enzyme regulation in
gluconeogenesis. We found miR-182, a potential modulator of
FOXO1 to be down-regulated in T2D but was slightly up-regulated
in IFG (Fig. 5B, 6A). Correspondingly, FOXO1 mRNA was
negatively regulated in IFG while showing positive fold change in
T2D (Fig. 5C, 6B), suggesting hepatic gluconeogenesis to have a
compensatory reduction in IFG, but increased in T2D.
Although our results were in conjunction with earlier studies
which identified miR-192, miR-29a, miR-320 and miR-30d to be
potential key players in the pathogenesis of T2D, we do observe
differences in the recent study reported by Zampetaki et al [20].
The authors discussed the loss of endothelial miR-126 and other
miRNAs in T2D. Among the miRNAs they identified, similarities
in miRNA changes were observed in miR-20b, miR-191 and miR-
197 which were down-regulated. We also observe the same in
almost all of our IFG samples and more than 50% of our T2D
samples. Zampetaki et al [20] identified miR-126 as a characteristic
miRNA in T2D and demonstrated that it is involved in endothelial
dysfunction. We do not observe a similar down-regulation of miR-
126 in our samples. This could be explained by the fact that we
have exclusively used subjects that were not on any medications
and do not show abnormalities in cholesterol, blood pressure and
BMI. A separate study by Gallagher et al [61] performed miRNA
profiling using total RNA extracted from muscle tissue biopsies of
individuals with insulin resistance. The samples that were used by
Gallagher et al were different from ours in terms of ethnicity and
BMI (individuals in Gallagher et al study are considered obese),
also some of them were receiving medications. These differences
could again contribute to the discrepancies in our results.
Nonetheless, the authors identified a pool of dysregulated miRNAs
(,50 miRNAs) in which some of them such as miR-144, miR-
106b, miR-185, miR-30e, miR-589, miR-665 and many more
showed similarities in expression as observed in our study (either
humans/animals or both). Moreover, miR-144 was also found to
be the most highly expressed miRNA in their T2D samples. Our
study correlated quite closely with another study reported recently
by Kong et al [59] which is based on a Chinese population. The
authors investigated the expression of seven diabetes-related
miRNAs (miR-9, miR-29a, miR-30d, miR-34a, miR-124a, miR-
146a and miR-375), four (miR-29a, miR-30d, miR-175 and miR-
146a) of which were also found to be dysregulated in our study.
Exosomal miRNAs and mRNAs
Several studies have reported how microvesicles such as
exosomes could serve as a transport machinery of miRNAs,
mRNAs and proteins [27] to mediate cell-to-cell communication.
In our study, the whole blood was used as a source of miRNAs
since it will include all possible sources of circulating miRNAs such
as the leukocytes, plasma, serum and exosomes. Additionally, we
also studied the expression of the potential ‘signature miRNAs’ of
T2D in exosomes isolated from serum of our rat T2D model. As
expected, the expression pattern of exosomal miRNAs was shown
to be consistent with that we observed in whole blood but at a
lower level. This could be due to the whole blood encompassing
the other sources of miRNAs apart from those of exosomes alone.
miR-144 as an important key player in T2D
Among the eight miRNAs identified as potential signature
miRNAs, miR-144 has shown to be a potential novel key player in
T2D. Here, miR-144 expression is highly up-regulated in T2D
and it also seemed to exhibit a linear relationship with increasing
glycaemic status (Fig. 5B, 6A). Focusing our interest in miR-144,
we next looked into its corresponding IRS1 target at protein level.
Using Western blot analysis, we have clearly demonstrated a
decreased IRS1 protein content in IFG and T2D (Fig. 9). This
result is in conjunction with our hypothesis that miR-144
negatively modulates IRS1. Tyr
612-phospho-IRS1 was markedly
reduced in T2D, while Ser
636+639-phospho-IRS1, responsible in
inhibiting the insulin signaling cascade [53,54] was increased in
T2D (Fig. 9).
To confirm that IRS1 is a target of miR-144, we observed the
corresponding changes in IRS1 mRNA level upon treatment with
either pre- or anti- miR-144 (Fig. 11B, 11C). Introduction of pre-
miR-144 greatly inhibited IRS1 mRNA level while treatment with
anti-miR-144 resulted in increased IRS1 mRNA expression
(Fig. 11C). Similar observations were obtained in the immunocy-
tochemistry assay which indicates that inhibition of IRS1 by miR-
144 at protein level (Fig. 11D). These observations together with
the luciferase binding assays (Fig. 10) demonstrate that miR-144
functions as a modulator of IRS1 expression. Hence, miR-144
could serve as a potential therapeutic target in T2D.
In our study, we have shown that circulating blood miRNAs are
appropriate indicators of disease development. We have also
identified eight important miRNAs (miR-144, miR-146a, miR-
150, miR-182, miR-192, mir-29a, miR-30d and miR-320) that
could participate in the regulation of insulin signaling as well as
useful in distinguishing different stages of diabetes progression.
These findings can contribute to the existing knowledge on the
role of miRNAs in glucose metabolism, diabetes and its related
complications. Among these miRNAs, we have identified miR-144
as a direct modulator of IRS1 and hence a potential therapeutic
target of T2D. Nonetheless, further investigations using animal
models as well as more human samples have to be carried out to
validate our findings and to further elucidate the mechanisms of
miRNA regulatory network in the pathogenesis of T2D.
Methods
Animal care and sample collection
Male Wistar rats, 6 weeks of age and weighing approximately
150 g were used for all studies. The animals were handled
according to the guidelines of the Council for International
Organization of Medical Sciences on Animal Experimentation
(World Health Organization, Geneva, Switzerland) and the
National University of Singapore. The animal protocols were
approved (approved code 062/09) by the National University of
Singapore Institutional Animal Care and Use committee.
Induction of Type 2 diabetes was done according to Reed et al
[45] with some modifications. After one week of acclimatization,
twelve rats were randomly divided into two groups equally. One
group was fed with normal fat diet (NFD) consisting of (as
percentage of total kcal) 18% fat, 58% carbohydrate and 24%
protein (Harlan Teklad, 2018, Madison, WI) and the other with
high fat diet (HFD) consisting of 39% fat, 40% carbohydrate and
21% protein (Specialty Feeds, SF10-019, Western Australia). After
two weeks the animals on HFD were injected with low dose of
STZ (40 mg/kg) intra-peritoneally after an overnight fast. Both
groups of animals were continued on their respective diets (NFD
or HFD) for another week [43,45]. A combination of high fat diet
and low dose of STZ has been found to show characteristics
closely related to T2D in contrast to administration of high STZ
alone which mimics Type 1 diabetes [46–48]. At the end of the
experimental period (on the 8
th day after STZ administration),
animals were euthanized using CO2 and blood and tissue samples
(pancreas, liver, adipose and skeletal muscle) were harvested and
washed in cold saline. Serum was separated by centrifugation and
analyzed for concentrations of glucose, insulin and triglycerides.
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exosome precipitation kit (SystemBio, CA, USA) followed by
exosomal total RNA isolation according to the manufacturer’s
protocol. Both blood and tissue samples were preserved at 280uC
for subsequent analysis.
Oral glucose tolerance test
To assess oral glucose tolerance, animals were fasted overnight
and their serum glucose response to the oral administration (by
oral gavage) of a solution of 20% glucose (2 g/kg) was determined.
Blood was drawn from tail at time 0, 15, 30, 60 and 120 minutes
after administration of glucose. Glucose and insulin concentrations
were analyzed.
Islet isolation and culture
Pancreatic islets were isolated by collagenase digestion as
previously described [62,63]. Briefly, the pancreas was perfused
with a solution of 0.5 mg/ml Collagenase Type V (Sigma, USA)
dissolved in Hanks Balanced Salt Solution (HBSS). The digestion
was performed at 37uC for 20–30 min after which the collagenase
was neutralized with HBSS supplemented with 1% FBS. The
collagenase treated pancreas was then sequentially filtered through
1.5 mm and 0.8 mm metal mesh filters. Islets were subsequently
enriched by centrifugation in Histopaque 1077 (Sigma, USA) and
hand-picked under direct light microscopic visualization. Isolated
islets were cultured in 24-well plate at 100 islets per well containing
DMEM medium (Sigma, USA) supplemented with 2 mM L-
glutamine (Gibco, USA), 10% fetal bovine serum (Gibco, USA),
100 U/ml penicillin and 100 mg/ml streptomycin (Pen-Strep; Bio-
Whittaker Europe, Verviers, Belgium), and 5.0 mmol/l glucose.
After 24 h incubation at basal glucose concentration (5.0mmol/l),
islets were transferred to either basal (5.0 mM) or high (25.0 mM)
glucose in DMEM for 24 h. Total RNA was isolated from islets
using the Trizol reagent according to the manufacturer’s protocol.
Patients
We consecutively enrolled all consenting male adult subjects (21
to 70 years of age) with no past medical history, seen in Alexandra
Hospital (Singapore) for health screening during the period of July
2008 to April 2009. This study was approved by our institutional
ethics review board (Ministry of Health, Singapore; MH95:03/1–
11) and all volunteers signed written informed consent. All subjects
were not on any medications and health-screening involved
physical examination including waist circumference, other an-
thropometric measures and blood pressure. Blood was collected in
fluoride oxalate tubes after an overnight fast of 10 to 12 hours.
Plasma glucose was obtained by enzymatic methods (ADVIA
2400, Bayer Diagnostics), while serum total cholesterol (TC),
triglyceride (TG), low-density lipoprotein (LDL) and high-density
lipoprotein (HDL) levels were measured using an automated
analyzer (ADVIA 2400, Bayer Diagnostics). Blood samples were
then categorized into 3 distinct groups, based on the World Health
Organization (WHO) and International Diabetes Federation (IDF)
[64]: Healthy controls (CTL, n=15) with fasting glucose ,6.1
mmol/L, Impaired Fasting Glucose (IFG, n=14) with fasting
glucose above 6.0mmol/l but less than 7.0 mmol/L and Type 2
Diabetes (T2D, n=21) with fasting glucose greater or equal to
7.0mmol/L (Table 2- Batches A and B). All were normotensive
(blood pressure #140/90), with desirable cholesterol levels (LDL
#3.4 mmol/L) and body mass index (BMI #27 which indicates
that they are not obese) [52]. For miRNA studies, whole blood
samples collected separately in tubes containing RNALater were
used. miRNA signatures in Batch A samples were confirmed
independently by quantitative real-time PCR with samples from
Batch B. All controls were age-matched to the respective cohort
(Table 2).
Total RNA Isolation
Total RNA (+ miRNAs) was isolated using a modification of the
RiboPure
TM-Blood kit from Ambion (Austin,TX) according to the
manufacturer’s protocol. The concentration of total RNA and
integrity were determined by using Nano-Drop ND-1000
Spectrophotometry (NanoDrop Tech, Rockland, Del) and gel
electrophoresis respectively.
mRNA and microRNA microarray
The oligonucleotide (DNA) microarray was performed accord-
ing to manufacturer’s protocol (Illumina, SanDiego, USA) using
500 ng of total RNA. Biotin-labelled complementary RNA probes
were synthesized with the Illumina TotalPrep RNA Amplification
kit (Ambion). Gene profiling was performed with Sentrix
BeadChip Array HumanRef-8 v2 (Illumina). Data were analysed
with the BeadStudio software. Differentially expressed genes were
selected based on the following parameters as suggested by the
manufacturers were used: p value ,0.05, Diff score .20, Average
signal .100. LNA-modified oligonucleotide (Exiqon, USA) probes
for human, mouse and rat miRNAs annotated in miRBase version
11.0 were used in the microarray. Total RNA (1 mg) was 39-end –
labeled with Hy3 dye using the miRCURY LNA
TM Power
Labeling Kit (Exiqon, USA) and hybridized on miRCURY
LNA
TM Arrays, using MAUIH hybridization system. Back-
ground-subtracted mean intensity of 300 was selected as a
threshold value before normalization against the U6 snRNA
[65]. For comparisons of miRNA profiles, data were expressed as
fold change of case versus healthy control. Hierarchical clustering
plot (heatmap) and Principal Component Analysis (PCA) were
generated as shown by Tan et al [18], using TIGR multiple
experimental viewer software. Microarray data were deposited in
Gene Expression Omnibus (GEO) with accession numbers stated
accordingly under the ‘Results’ section.
Stem-loop real-time RT-PCR and real-time PCR
The miRNA microarray results were validated with stem-loop
real-time RT-PCR [66,67]. Eight miRNAs were selected for this
validation using specific stem-loop primers (Applied Biosystems,
USA). Expression of corresponding predicted mRNA targets to
these selected miRNAs were also validated by real-time PCR using
gene specific primers. Both reverse transcription and PCRs were
performed in triplicates in at least 3 independent experiments on
an Applied Biosystems 7900 sequence detection system.
SDS-PAGE and Western Blot Analysis
Serum samples (40 ug) depleted of albumin and IgG were
resolved using 10% SDS-PAGE. Western blot was carried out as
described in Jeyaseelan et al [66]. The primary rabbit polyclonal
anti-human antibodies against IRS1, Tyr
612-phospho-IRS1 and
Ser
636+639-phospho-IRS1 were added at a 1:2000 dilution in
PBST containing 2.5% non-fat dry milk for 60 min to identify
specific proteins. The membranes were washed in PBST followed
by incubation in secondary goat anti-rabbit antibody (1:5000
dilution) in PBST containing 2.5% non-fat dry milk for 60 min.
The membranes were washed again with PBST and visualized
with Super-Signal West-Dura Extended Duration Substrate
(Pierce, Biotechnology, USA) and developed in Kodak Biomax
film. Films of Western blots were scanned (Acer SWZ3300U), and
the labeling intensities of the bands were quantified using ImageJ
software (National Institutes of Health). Relative expression of
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to that in control samples. All band images were representatives of
at least three independent experiments.
Dual Luciferase reporter assay
HeLa cells were used in our immunocytochemistry and dual
luciferase reporter assays [55–57]. The 39UTR of IRS1 containing
the putative target site for miR-144 was amplified by PCR using
gene specific primers. PCR products were cloned into Firefly-luc-
expressing vector pMIR-REPORT
TM, Ambion (Austin,TX)) at
the Spe1/HindIII site. Plasmid transfection procedure was
adapted from Cheng et al [55]. HeLa cells cultured in 24-well
plates were transfected with 50 nM anti miR-144 or pre miR-144
for 3hrs followed by 200 ng/well pMIR-REPORT constructs for
3 hrs. The cells were left to recover for 48 hrs before being lysed
for measurement of luciferase activity. Dual luciferase assay
(Promega, USA) was used to quantitate the effects of anti or pre
miR-144 interaction with the 39 UTR of IRS1. The assay was
performed according to manufacturer’s protocol. In all experi-
ments, transfection efficiencies were normalized to those of cells
co-transfected with the Renilla-luc-expressing vector pRL-CMV
(Promega, USA) at 10 ng/well.
Immunocytochemistry
Immunocytochemistry was also performed on HeLa cells
transfected with either pre miR-144 or anti miR-144 [66]. The
cells were fixed with 4% paraformaldehyde in PBS and blocked
with 5% FBS before incubation with rabbit anti-human antibody
IRS1 for 1 h at room temperature. Goat anti-rabbit FITC labeled
secondary antibody was used. Cells were mounted and nuclei were
counterstained with Hoechst 33342 and viewed under a
fluorescence microscope (Carl Zeiss LSM 510 META).
Statistical analysis
Microarray Analysis was carried out according to our previously
published report [18] which involved multiple sample analysis
including background subtraction, t-Test/One-way ANOVA
analysis, hierarchical clustering and principal component analysis.
Normalization was performed against U6 snRNA [18]. t-Test was
performed between ‘‘control’’ and ‘‘test’’ sample groups and t-
values were calculated for each miRNA. p-values were computed
from the theoretical t-distribution. The microarray data reported
in this manuscript is described in accordance with MIAME
guidelines. The clustering using hierarchical method was per-
formed with average linkage and Euclidean distance metric. The
clustering and principal component analysis (PCA) plot was
generated using TIGR MeV (Multiple Experimental Viewer)
software [18]. Other statistical data evaluation was performed
using two-tailed t-tests or in case of multiple comparisons using
One-way ANOVA along with Fisher’s least significance difference
test [65]. The significance level was p,0.05.
Supporting Information
Table S1 MicroRNA microarray results of T2D rat
model (Fig. 2A). Only miRNAs that are conserved in both
human and rats, and with background subtracted mean signal
intensities above 300 are included. Filtered signal intensities were
normalized against U6snRNA. Values shown are fold changes
calculated as a ratio of T2D versus control 6 SEM. The grey
boxes indicate negative expression values. Array data can be
accessed from Gene Expression Omnibus (GEO) with accession
no. GSE26167; SuperSeries GSE26168. T2D, type 2 diabetes.
(DOC)
Table S2 microRNAs expression in rat blood, liver,
pancreas, skeletal muscle and adipose tissues. miRNAs
that were filtered using the statistical analysis as described in the
‘‘Methods section’’ were further subjected to fold change analysis.
Statistically significant differences are tested using Student’s t-test
at p,0.05 significance Fold change values are calculated as a ratio
of T2D versus respective control 6 SEM. Fold change values
below 1 are expressed in negative values. miRNAs that exhibited
at least61.5 fold change have been included. miRNAs that are
highly up/down regulated in all sources are marked in bold. Only
miRNAs conserved in both humans and rats are shown. T2D,
type 2 diabetes.
(DOC)
Table S3 MicroRNA microarray results of both indi-
vidual and pooled samples (Fig. 4A). miRNA that were
filtered using the statistical analysis as described in the ‘‘Methods
section’’ were further subjected to fold change analysis. Filtered
signal intensities were normalized against U6snRNA. Values are
fold changes calculated as a ratio of IFG or T2D versus control
(CTL) 6 SEM. Array have been deposited in the Gene Expression
Omnibus (GEO) database and can be accessed with accession
no. GSE21321; SuperSeries GSE26168. IFG, impaired fasting
glucose; T2D, type 2 diabetes.
(XLS)
Table S4 miRNAs expressed in IFG and T2D from batch
A. miRNAs whose significant changes replicated in at least 50% of
the subjects in any of the two categories (IFG; n=6, or T2D;
n=8) as compared to CTL; (n=7) are shown. Values of miRNAs
that were differentially expressed but showed no significant fold
change (p.0.05) in at least 50% of the subjects in any of the two
categories were not included. Values are fold changes calculated as
a ratio of IFG or T2D versus control (CTL) with p-values in 2
decimal places. Fold change values below 1 are expressed as the
negative values. Statistically significant differences are tested using
Student’s t-test at p,0.05 significance. miRNAs that are
significantly expressed in both IFG and T2D are shown in bold.
CTL, healthy controls; IFG, impaired fasting glucose; T2D, type 2
diabetes.
(DOC)
Table S5 Pearson correlation scatter plot of miRNA
expressions (BatchA). (A). miRNA profiles of IFG patients do
not correlate strongly to those of CTL at R=0.78; in white circles
while (B). the miRNA profiles of T2D patients showed a much
weaker correlation to CTL at a further reduced R=0.68; in white
squares. The scatter plot of ,100 detected miRNAs is drawn to
provide a snap shot of the distribution and the correlation between
the two variables. Points closely clustered to a straightline indicate
a stronger correlation between the variables.The plot shows that
IFG and CTL has stronger association than T2D and CTL.
CTL,healthy controls; IFG,impaired fasting glucose; T2D,type 2
diabetes.
(PDF)
Table S6 Table shows mRNA microarray fold change
values of IFG or T2D vs healthy control. The values were
used to construct the Principal Component Analysis (PCA) plot as
in Table S7. Biotin-labelled complementary RNA probes were
synthesized with the Illumina TotalPrep RNA Amplification kit
(Ambion). Gene profiling was performed with Sentrix BeadChip
Array HumanRef-8 v2 (Illumina). Data were analysed with the
BeadStudio software. Differentially expressed genes were selected
based on the following parameters as suggested by the manufac-
turer: p value ,0.05, Diff score .20, Average signal .100. All
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(GEO) with accession no. GSE21321; SuperSeries GSE26168.
CTL, healthy controls; IFG, impaired fasting glucose; T2D, type 2
diabetes.
(XLS)
Table S7 PCA plot of mRNA profiles of IFG and T2D
patients (Batch A). Principal component analysis (PCA) plot
based on mRNA expression showed a less distinguished
classification of IFG and T2D patients. Batch A patients consists
of six IFG patients (labeled as 1IFG to 6IFG) and eight T2D
patients (labeled as 1T2D to 8T2D). IFG,impaired fasting glucose;
T2D,type 2 diabetes.
(PDF)
Table S8 Validation of microRNAs and mRNAs micro-
array. The microarray data for the expression of the 8
‘‘signature’’ miRNAs and their respective target mRNAs were
validated using quantitative real-time PCR. Each miRNA/mRNA
were assayed in triplicates for 3 separate experiments and the
relative expression values are stated 6 SEM. Fold change for the
real-time PCR data was computed from the 2
2DDCt values.
Statistically significant differences are tested using Student’s t-test
at p,0.05 significance. CTL, healthy controls; IFG, impaired
fasting glucose; T2D, type 2 diabetes.
(DOC)
Table S9 Quantitative Real-time PCR results for Batch
B individuals (Fig. 6A&B). The 8 ‘‘signature’’ miRNAs (A) and
their respective target mRNAs (B) were validated using quantita-
tive real-time PCR in the Batch B blood samples. Each miRNA/
mRNA were assayed in triplicates for 3 separate experiments and
the relative expression values are stated 6 SEM. Fold change for
the real-time PCR data was computed from the 2
2DDCt values.
Statistically significant differences are tested using Student’s t-test
at p,0.05 significance. CTL, healthy controls; IFG, impaired
fasting glucose; T2D, type 2 diabetes.
(DOC)
Table S10 Expression of miRNAs and mRNAs in rat
models. (A) Endogenous expression levels of (abundance) of
miRNAs and mRNAs in control tissues (adipose, pancreas, skeletal
muscle and liver), blood and exosomes of rat model were assayed
using quantitative real-time PCR analysis and expressed as delta
threshold cycle (DCt) value with respect to 18S rRNA. Lower DCt
value indicates higher expression levels. (B) Stem-loop RT-PCR
results for T2D rat model induced by a combination of low dose
STZ (40 mg/kg) and high-fat diet (Fig. 7A) (C) Quantitative Real-
time PCR results for the 8 ‘‘signature’’ miRNA (B) respective
target mRNA in T2D rat model (Fig. 7B). Expression values (B &
C) are tabulated as fold change calculated as a ratio of T2D versus
control, 2
2DDCt 6 SEM. Fold change below 1 are expressed as the
negative reciprocal value. Validation for each miRNA/mRNA
were assayed in triplicates for 3 separate experiments. T2D, type 2
diabetes.
(DOC)
Table S11 Quantitative Real-time PCR miRNA (A) and
mRNA (B) analysis for islet primary culture (Fig. 8A&B).
Expression values are tabulated as fold change calculated as a ratio
of high glucose (25 mM) versus basal glucose control (5 mM) ratio
of T2D versus control, 2
2DDCt 6 SEM. Fold change below 1 are
expressed as the negative reciprocal value. Validation for each
miRNA/mRNA was assayed in triplicates for 3 separate
experiments.
(DOC)
Table S12 Binding sites of miR-144 at 39UTR of IRS1
and mutated constructs of the binding sites. 39UTR of
IRS1 contains two miR-144 binding sites (highlighted). Fragment
with 1
st binding site of miR-144 alone includes 39UTR of IRS1
from 3781-4201bp, while fragment with 2
nd binding site of
miR144 alone includes 39UTR of IRS1 from 4501-4921bp.
Fragment with both binding sites of miR-144 includes 39UTR of
IRS1 from 3781-4921bp. Seed region if miR-144 is shown in bold
italics. Mutations are marked with asterisks.
(DOC)
Author Contributions
Conceived and designed the experiments: KJ. Performed the experiments:
DSK AA. Analyzed the data: DSK AA KJ ST. Contributed reagents/
materials/analysis tools: KJ ST MTKW SCL CFS. Wrote the paper: DSK
KJ AA. Clinical collaborators who conducted the health screening and
provided blood samples for the study: ST MTKW SCL CFS. Principal
investigator for the project: KJ.
References
1. Lee RC, Feinbaum RL, Ambros V (1993) The C. elegans heterochronic gene
lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75:
843–854.
2. Pillai RS, Bhattacharyya SN, Filipowicz W (2007) Repression of protein
synthesis by miRNAs: how many mechanisms? Trends Cell Biol 17: 118–126.
3. Li LC, Okino ST, Zhao H, Pookot D, Place RF, et al. (2006) Small dsRNAs
induce transcriptional activation in human cells. Proc Natl Acad Sci U S A 103:
17337–17342.
4. Janowski BA, Younger ST, Hardy DB, Ram R, Huffman KE, et al. (2007)
Activating gene expression in mammalian cells with promoter-targeted duplex
RNAs. Nat Chem Biol 3: 166–173.
5. Vasudevan S, Tong Y, Steitz JA (2007) Switching from repression to activation:
microRNAs can up-regulate translation. Science 318: 1931–1934.
6. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R (2008) MicroRNA-373
induces expression of genes with complementary promoter sequences. Proc Natl
Acad Sci U S A 105: 1608–1613.
7. Shcherbata HR, Hatfield S, Ward EJ, Reynolds S, Fischer KA, et al. (2006) The
MicroRNA pathway plays a regulatory role in stem cell division. Cell Cycle 5:
172–175.
8. Shivdasani RA (2006) MicroRNAs: regulators of gene expression and cell
differentiation. Blood 108: 3646–3653.
9. Kuhn DE, Nuovo GJ, Martin MM, Malana GE, Pleister AP, et al. (2008)
Human chromosome 21-derived miRNAs are overexpressed in down syndrome
brains and hearts. Biochem Biophys Res Commun 370: 473–477.
10. Li Y, Lin L, Jin P (2008) The microRNA pathway and fragile X mental
retardation protein. Biochim Biophys Acta 1779(11): 702–5.
11. Weber JA, Baxter DH, Zhang S, Huang DY, Huang KH, et al. (2010) The
microRNA spectrum in 12 body fluids. Clin Chem 56: 1733–1741.
12. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, et al. (2008)
Circulating microRNAs as stable blood-based markers for cancer detection. Proc
Natl Acad Sci U S A 105: 10513–10518.
13. Heneghan HM, Miller N, Lowery AJ, Sweeney KJ, Newell J, et al. (2010)
Circulating microRNAs as novel minimally invasive biomarkers for breast
cancer. Ann Surg 251: 499–505.
14. Vlassov VV, Laktionov PP, Rykova EY (2010) Circulating nucleic acids as a
potential source for cancer biomarkers. Curr Mol Med 10: 142–165.
15. Tijsen AJ, Creemers EE, Moerland PD, de Windt LJ, van der Wal AC, et al.
(2010) MiR423-5p As a Circulating Biomarker for Heart Failure. Circ Res 106:
1035–1039.
16. Hoekstra M, van der Lans CA, Halvorsen B, Gullestad L, Kuiper J, et al. (2010)
The peripheral blood mononuclear cell microRNA signature of coronary artery
disease. Biochem Biophys Res Commun 394(3): 792–7.
17. Cortez MA, Calin GA (2009) MicroRNA identification in plasma and serum: a
new tool to diagnose and monitor diseases. Expert Opin Biol Ther 9: 703–711.
18. Tan KS, Armugam A, Sepramaniam S, Lim KY, Setyowati KD, et al. (2009)
Expression profile of MicroRNAs in young stroke patients. PLoS One 4: e7689.
19. Chen X, Ba Y, Ma L, Cai X, Yin Y, et al. (2008) Characterization of
microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and
other diseases. Cell Res 18: 997–1006.
20. Zampetaki A, Kiechl S, Drozdov I, Willeit P, Mayr U, et al. (2010) Plasma
microRNA profiling reveals loss of endothelial miR-126 and other microRNAs
in type 2 diabetes. Circ Res 107: 810–817.
MicroRNAs and Type 2 Diabetes
PLoS ONE | www.plosone.org 18 August 2011 | Volume 6 | Issue 8 | e2283921. Laterza OF, Lim L, Garrett-Engele PW, Vlasakova K, Muniappa N, et al.
(2009) Plasma MicroRNAs as sensitive and specific biomarkers of tissue injury.
Clin Chem 55: 1977–1983.
22. Kosaka N, Iguchi H, Yoshioka Y, Takeshita F, Matsuki Y, et al. (2010) Secretory
mechanisms and intercellular transfer of microRNAs in living cells. J Biol Chem
285(23): 17442–52.
23. Michael A, Bajracharya SD, Yuen PS, Zhou H, Star RA, et al. (2010) Exosomes
from human saliva as a source of microRNA biomarkers. Oral Dis 16: 34–38.
24. Pisitkun T, Shen RF, Knepper MA (2004) Identification and proteomic profiling
of exosomes in human urine. Proc Natl Acad Sci U S A 101: 13368–13373.
25. Caby MP, Lankar D, Vincendeau-Scherrer C, Raposo G, Bonnerot C (2005)
Exosomal-like vesicles are present in human blood plasma. Int Immunol 17:
879–887.
26. Rabinowits G, Gercel-Taylor C, Day JM, Taylor DD, Kloecker GH (2009)
Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer
10: 42–46.
27. Mathivanan S, Ji H, Simpson RJ (2010) Exosomes: extracellular organelles
important in intercellular communication. J Proteomics 73: 1907–1920.
28. Abdul-Ghani MA, DeFronzo RA (2009) Pathophysiology of prediabetes. Curr
Diab Rep 9: 193–199.
29. Campbell RK (2009) Type 2 diabetes: where we are today: an overview of
disease burden, current treatments, and treatment strategies. J Am Pharm Assoc
(2003) 49 Suppl 1: S3–9.
30. Tavintharan S, Chi LS, Fang SC, Arunmozhiarasi A, Jeyaseelan K (2009)
Riboregulators and metabolic disorders: getting closer towards understanding
the pathogenesis of diabetes mellitus? Curr Mol Med 9: 281–286.
31. Poy MN, Eliasson L, Krutzfeldt J, Kuwajima S, Ma X, et al. (2004) A pancreatic
islet-specific microRNA regulates insulin secretion. Nature 432: 226–230.
32. Xia HQ, Pan Y, Peng J, Lu GX (2010) Over-expression of miR375 reduces
glucose-induced insulin secretion in Nit-1 cells. Mol Biol Rep. Epub ahead of
print.
33. Krek A, Grun D, Poy MN, Wolf R, Rosenberg L, et al. (2005) Combinatorial
microRNA target predictions. Nat Genet 37: 495–500.
34. He A, Zhu L, Gupta N, Chang Y, Fang F (2007) Overexpression of micro
ribonucleic acid 29, highly up-regulated in diabetic rats, leads to insulin
resistance in 3T3-L1 adipocytes. Mol Endocrinol 21: 2785–2794.
35. Kato M, Zhang J, Wang M, Lanting L, Yuan H, et al. (2007) MicroRNA-192 in
diabetic kidney glomeruli and its function in TGF-beta-induced collagen
expression via inhibition of E-box repressors. Proc Natl Acad Sci U S A 104:
3432–3437.
36. Wang Q, Wang Y, Minto AW, Wang J, Shi Q, et al. (2008) MicroRNA-377 is
up-regulated and can lead to increased fibronectin production in diabetic
nephropathy. Faseb J 22: 4126–4135.
37. Herrera BM, Lockstone HE, Taylor JM, Ria M, Barrett A, et al. (2010) Global
microRNA expression profiles in insulin target tissues in a spontaneous rat
model of type 2 diabetes. Diabetologia 53: 1099–109.
38. Zhao E, Keller MP, Rabaglia ME, Oler AT, Stapleton DS, et al. (2009) Obesity
and genetics regulate microRNAs in islets, liver, and adipose of diabetic mice.
Mamm Genome 20: 476–485.
39. Herrera BM, Lockstone HE, Taylor JM, Wills QF, Kaisaki PJ, et al. (2009)
MicroRNA-125a is over-expressed in insulin target tissues in a spontaneous rat
model of Type 2 Diabetes. BMC Med Genomics 2: 54.
40. Huang B, Qin W, Zhao B, Shi Y, Yao C, et al. (2009) MicroRNA expression
profiling in diabetic GK rat model. Acta Biochim Biophys Sin (Shanghai) 41:
472–477.
41. Lv K, Guo Y, Zhang Y, Wang K, Jia Y, et al. (2008) Allele-specific targeting of
hsa-miR-657 to human IGF2R creates a potential mechanism underlying the
association of ACAA-insertion/deletion polymorphism with type 2 diabetes.
Biochem Biophys Res Commun 374: 101–105.
42. Kloting N, Berthold S, Kovacs P, Schon MR, Fasshauer M, et al. (2009)
MicroRNA expression in human omental and subcutaneous adipose tissue.
PLoS One 4: e4699.
43. Wang HJ, Jin YX, Shen W, Neng J, Wu T, et al. (2007) Low dose streptozotocin
(STZ) combined with high energy intake can effectively induce type 2 diabetes
through altering the related gene expression. Asia Pac J Clin Nutr 16 Suppl 1:
412–417.
44. Srinivasan K, Viswanad B, Asrat L, Kaul CL, Ramarao P (2005) Combination
of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2
diabetes and pharmacological screening. Pharmacol Res 52: 313–320.
45. Reed MJ, Meszaros K, Entes LJ, Claypool MD, Pinkett JG, et al. (2000) A new
rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism
49: 1390–1394.
46. Cheng JT, Liu IM, Chi TC, Tzeng TF, Lu FH, et al. (2001) Plasma glucose-
lowering effect of tramadol in streptozotocin-induced diabetic rats. Diabetes 50:
2815–2821.
47. Nasrallah R, Hebert RL (2004) Reduced IP receptors in STZ-induced diabetic
rat kidneys and high-glucose-treated mesangial cells. Am J Physiol Renal Physiol
287: F673–681.
48. Sachin Arora, Shreesh Kumar Ojha, Divya Vohora (2009) Characterisation of
Streptozotocin Induced Diabetes Mellitus in Swiss Albino Mice. Global J
Pharmacol 3(2): 81–84.
49. Tang X, Muniappan L, Tang G, Ozcan S (2009) Identification of glucose-
regulated miRNAs from pancreatic {beta} cells reveals a role for miR-30d in
insulin transcription. Rna 15: 287–293.
50. Ling HY, Ou HS, Feng SD, Zhang XY, Tuo QH, et al. (2009) Changes in
microRNA profile and effects of miR-320 in insulin-resistant 3T3-L1 adipocytes.
Clin Exp Pharmacol Physiol Epub ahead of print.
51. Wang XH, Qian RZ, Zhang W, Chen SF, Jin HM, et al. (2009) MicroRNA-320
expression in myocardial microvascular endothelial cells and its relationship with
insulin-like growth factor-1 in type 2 diabetic rats. Clin Exp Pharmacol Physiol
36: 181–188.
52. Yajnik CS, Yudkin JS (2004) Appropriate body-mass index for Asian populations
and its implications for policy and intervention strategies. Lancet 363: 157–163.
53. Esposito DL, Li Y, Cama A, Quon MJ (2001) Tyr(612) and Tyr(632) in human
insulin receptor substrate-1 are important for full activation of insulin-stimulated
phosphatidylinositol 3-kinase activity and translocation of GLUT4 in adipose
cells. Endocrinology 142: 2833–2840.
54. Bouzakri K, Roques M, Gual P, Espinosa S, Guebre-Egziabher F, et al. (2003)
Reduced activation of phosphatidylinositol-3 kinase and increased serine 636
phosphorylation of insulin receptor substrate-1 in primary culture of skeletal
muscle cells from patients with type 2 diabetes. Diabetes 52: 1319–1325.
55. Cheng AM, Byrom MW, Shelton J, Ford LP (2005) Antisense inhibition of
human miRNAs and indications for an involvement of miRNA in cell growth
and apoptosis. Nucleic Acids Res 33: 1290–1297.
56. Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, et al. (2004) Absence of
S6K1 protects against age- and diet-induced obesity while enhancing insulin
sensitivity. Nature 431: 200–205.
57. Wang C, Mao X, Wang L, Liu M, Wetzel MD, et al. (2007) Adiponectin
sensitizes insulin signaling by reducing p70 S6 kinase-mediated serine
phosphorylation of IRS-1. J Biol Chem 282: 7991–7996.
58. Roggli E, Britan A, Gattesco S, Lin-Marq N, Abderrahmani A, et al.
Involvement of microRNAs in the cytotoxic effects exerted by proinflammatory
cytokines on pancreatic beta-cells. Diabetes 59: 978–986.
59. Kong L, Zhu J, Han W, Jiang X, Xu M, et al. (2011) Significance of serum
microRNAs in pre-diabetes and newly diagnosed type 2 diabetes: a clinical
study. Acta Diabetol 48: 61–9.
60. Lizcano JM, Alessi DR (2002) The insulin signalling pathway. Curr Biol 12:
R236–238.
61. Gallagher IJ, Scheele C, Keller P, Nielsen AR, Remenyi J, et al. (2010)
Integration of microRNA changes in vivo identifies novel molecular features of
muscle insulin resistance in type 2 diabetes. Genome Med 2: 9.
62. Saeki K, Zhu M, Kubosaki A, Xie J, Lan MS, et al. (2002) Targeted disruption
of the protein tyrosine phosphatase-like molecule IA-2 results in alterations in
glucose tolerance tests and insulin secretion. Diabetes 51: 1842–1850.
63. Wu JJ, Quijano C, Chen E, Liu H, Cao L, et al. (2009) Mitochondrial
dysfunction and oxidative stress mediate the physiological impairment induced
by the disruption of autophagy. Aging (Albany NY) 1: 425–437.
64. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus.
(1997) Report of the Expert Committee on the Diagnosis and Classification of
Diabetes Mellitus. Diabetes Care 20: 1183–1197.
65. Wagner-Ecker M, Schwager C, Wirkner U, Abdollahi A, Huber PE (2010)
MicroRNA expression after ionizing radiation in human endothelial cells.
Radiat Oncol 5: 25.
66. Sepramaniam S, Armugam A, Lim KY, Karolina DS, Swaminathan P, et al.
(2010) MicroRNA 320a functions as a novel endogenous modulator of
aquaporins 1 and 4 as well as a potential therapeutic target in cerebral
ischemia. J Biol Chem 285: 29223–29230.
67. Plaisance V, Abderrahmani A, Perret-Menoud V, Jacquemin P, Lemaigre F, et
al. (2006) MicroRNA-9 controls the expression of Granuphilin/Slp4 and the
secretory response of insulin-producing cells. J Biol Chem 281: 26932–26942.
68. Lovis P, Roggli E, Laybutt DR, Gattesco S, Yang JY, et al. (2008) Alterations in
microRNA expression contribute to fatty acid-induced pancreatic beta-cell
dysfunction. Diabetes 57: 2728–2736.
69. Baroukh N, Ravier MA, Loder MK, Hill EV, Bounacer A, et al. (2007)
MicroRNA-124a regulates Foxa2 expression and intracellular signaling in
pancreatic beta-cell lines. J Biol Chem 282: 19575–19588.
MicroRNAs and Type 2 Diabetes
PLoS ONE | www.plosone.org 19 August 2011 | Volume 6 | Issue 8 | e22839